Thus, given the growth inhibitory effects of TNJ on HER2/neu tumors and the lack of adverse effects in the MMTV-neu model, TNJ may be able to enhance the manageability of HER2+ breast cancer to prolong patient survival when administered as a complementary therapy. This evidence concerns the gene ERBB2 and breast cancer.